British Journal of Dermatology

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

BACKGROUND: Conventional systemic drugs are used to treat children and young people (CYP) with severe atopic dermatitis (AD) worldwide, but no robust RCT evidence exists regarding their efficacy and safety in this population. While novel therapies have expanded therapeutic options, their high cost means traditional agents remain important, especially in lower resource settings. OBJECTIVES: The TREAT trial compared the safety and efficacy of ciclosporin (CyA) versus methotrexate (MTX) in CYP with severe AD...

Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic disabling and debilitating inflammatory disease with high unmet medical need. The prevalence of HS is 1-2% in most studies, although it is likely underreported and estimates vary globally due to variance in data collection methods, ethnicity, geographical location, and underdiagnosis. HS is characterized by persistent, painful cutaneous nodules, abscesses, and draining tunnels commonly affecting the axillary, anogenital, inguinal, and perianal/gluteal areas...

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

BACKGROUND: Baricitinib is approved for the treatment of adults with severe alopecia areata (AA). In the absence of robust data on the patterns of regrowth during treatment of severe AA, there is a gap in the knowledge regarding treatment expectations. OBJECTIVES: To examine whether different clinical response subgroups could be identified in baricitinib-treated patients with severe AA and factors that contribute to these subgroups. METHODS: The BRAVE-AA1 and BRAVE-AA2 phase III trials enrolled patients with severe AA [Severity of Alopecia Tool (SALT) score ≥ 50 (≥ 50% scalp hair loss)]...

BACKGROUND: Atopic dermatitis (AD) is the leading cause of the global burden from skin disease, while none of the study provides the global and country-specific AD epidemiological estimates. OBJECTIVE: To quantify global, regional, and country-specific estimates of epidemiology of AD. METHODS: A comprehensive search for AD epidemiological studies was conducted across four electronic databases-PubMed, EMBASE, Web of Science, and China National Knowledge Infrastructure...

No abstract text is available yet for this article.

No abstract text is available yet for this article.

BACKGROUND: Monoclonal antibodies to interleukin (IL)-17 have shown strong efficacy in patients with psoriasis. Izokibep is a unique IL-17A inhibitor with a small molecular size and favourable distribution to sites of inflammation. OBJECTIVES: To evaluate the dose response, efficacy and safety of izokibep in patients with plaque psoriasis. METHODS: In this double-blind, randomized, phase II dose-finding study (AFFIRM-35) in adults with moderate-to-severe plaque psoriasis and inadequate response to two or more standard therapies, patients were randomized (1:1:1:1:1) to placebo or izokibep 2, 20, 80 or 160 mg every 2 weeks for 12 weeks...

No abstract text is available yet for this article.

BACKGROUND: Cutaneous squamous cell carcinomas (SCC) are the leading cause of death in patients suffering from recessive dystrophic epidermolysis bullosa (RDEB). However, the survival time from first diagnosis differs among patients, and some tumours spread particularly fast, while others may remain localised over years. As treatment options are limited, there is an urgent need to provide further insights into the pathomechanisms elucidating the clinical heterogeneity of RDEB tumours to foster therapy development and support clinical decision-making...